Sign In
Free Newsletter
Bayer sues J&J over prostate cancer drug ads
Bayer filed suit against Johnson & Johnson, alleging false advertising of prostate cancer drug Erleada harmed sales of its rival treatment Nubeqa.
NJ pharma drugs among 15 targeted in Medicare price talks (updated)
CMS targets 15 high-spend drugs for Medicare price negotiations, including therapies from New Jersey-based Novartis, Johnson & Johnson and Bristol Myers Squibb.
Novartis’ $12B Avidity acquisition to expand neuroscience pipeline
The play for San Diego-based Avidity Biosciences will add RNA therapeutics that target rare genetic neuromuscular diseases.
Ascendis Pharma nearly doubles Princeton office
The Denmark-based company, which focuses on endocrine disease treatments, can now accommodate more than 100 employees at the 22,040-square-foot space.
Appeals court rejects NJ pharma challenges to Medicare drug pricing (updated)
New Jersey giants, including J&J, BMS and Novartis, have all lost challenges to the Inflation Reduction Act program, setting up the U.S. Supreme Court as the last lever remaining for potential relief.
Novo Nordisk to cut 9,000 jobs in global restructuring
The moves aim to save $1.3 billion annually by next year, streamline operations and increase focus on diabetes and obesity growth.
Novo Nordisk halves Ozempic price to $499 for US patients
As part of an effort to improve access to authentic versions of its GLP-1 medications, the drugmaker is cutting the cost of its popular diabetes drug.
Merck moves to cut $3B, jobs in latest restructuring
Along with its financial results for the second quarter of 2025, the Rahway company revealed plans that aim to save $1.7 million annually by the end of 2027.
NJBIZ list: Pharma companies grow, evolve across New Jersey
From J&J to BMS, New Jersey firms continue to expand and transform through M&A, leadership shifts and regional growth in 2025.
Pierre Fabre USA makes in-state HQ move to Secaucus
Pierre Fabre Laboratories relocated its stateside base from Parsippany to expand its dermo-cosmetics, rare disease and oncology efforts while staying rooted in New Jersey.
Sun Pharma names Ascroft North America CEO
Richard Ascroft is responsible for advancing the Princeton-based company’s portfolio of medicines, generics and over-the-counter products in the U.S. and Canada.
